Last updated: September 8, 2026
ARALAST NP is Takeda’s plasma-derived alpha1-proteinase inhibitor used for augmentation therapy in adults with severe hereditary alpha1-antitrypsin deficiency and emphysema. Its commercial position is shaped by a narrow diagnosed population, recurring weekly intravenous treatment, dependence on human plasma supply, and competition from Prolastin-C, Zemaira, and Glassia. Takeda does not separately report ARALAST NP revenue, so product-level sales, margins, and profitability cannot be quantified from public company filings.
What are ARALAST and ARALAST NP?
ARALAST and ARALAST NP are human alpha1-proteinase inhibitor products derived from pooled human plasma. The active protein is alpha1-proteinase inhibitor, also called alpha1-antitrypsin or A1PI.
| Product |
Active ingredient |
Company history |
Route |
Primary use |
| ARALAST |
Alpha1-proteinase inhibitor (human) |
Originally associated with Bayer and later Baxter |
Intravenous infusion |
Augmentation therapy for severe hereditary A1PI deficiency |
| ARALAST NP |
Alpha1-proteinase inhibitor (human), lyophilized formulation |
Baxter, Baxalta, Shire, now within Takeda’s portfolio |
Intravenous infusion |
Augmentation therapy for adults with emphysema from severe hereditary deficiency |
The U.S. prescribing information identifies ARALAST NP for chronic augmentation and maintenance therapy in adults with severe hereditary deficiency of alpha1-proteinase inhibitor and clinical evidence of emphysema.[1]
The treatment does not reverse established emphysema. Its commercial rationale is long-term replacement of the deficient circulating protein, generally administered at 60 mg/kg once weekly.[1]
What is the FDA regulatory status of ARALAST NP?
ARALAST NP is an FDA-approved biologic licensed under a biologics license application rather than approved as a conventional small-molecule drug. The product is regulated as a plasma-derived protein therapy.
Key regulatory characteristics include:
| Regulatory item |
ARALAST NP status |
| FDA product class |
Plasma-derived biologic |
| Active ingredient |
Alpha1-proteinase inhibitor (human) |
| Indication |
Chronic augmentation and maintenance therapy in adults with emphysema due to severe hereditary deficiency |
| Administration |
Intravenous infusion |
| Standard dose |
60 mg/kg weekly |
| Reference pathway |
Biologics license application |
| Generic pathway |
Not applicable in the conventional ANDA sense |
| Biosimilar pathway |
Potentially available under the Public Health Service Act, subject to FDA requirements |
| FDA exclusivity |
Historical biologic exclusivity has expired |
| Current commercial sponsor |
Takeda-related U.S. product portfolio |
FDA approval for ARALAST predates the current biosimilar framework. ARALAST NP is an updated formulation and manufacturing presentation rather than a new molecular entity.[1][2]
When does ARALAST NP lose exclusivity?
ARALAST NP’s principal regulatory exclusivity is no longer the main barrier to competition. The relevant commercial protection now comes from manufacturing controls, plasma sourcing, clinical know-how, supply reliability, reimbursement access, and physician familiarity.
The BPCIA provides 12 years of reference-product exclusivity for qualifying reference biologics approved under the modern framework.[3] ARALAST was approved before that framework took effect. Any historical exclusivity associated with its original approval would not prevent current biosimilar development.
No publicly identified, active exclusivity period provides ARALAST NP with a current 12-year market block comparable to a recently approved biologic.
ARALAST NP exclusivity timeline
| Date or period |
Event |
| 2003 |
FDA approval of ARALAST is associated with the original product approval history.[1] |
| 2010 |
ARALAST NP entered the U.S. market as the newer formulation and presentation.[1] |
| 2011 |
Baxalta’s predecessor business became part of the broader Baxter plasma-products platform. |
| 2016 |
Shire acquired Baxalta. |
| 2019 |
Takeda acquired Shire and assumed the relevant portfolio. |
| Present |
Commercial protection depends primarily on biologic manufacturing and supply barriers rather than unexpired statutory exclusivity. |
The exact distinction between product approval, formulation approval, and manufacturing supplements matters in evaluating any patent or exclusivity claim. Public FDA materials do not establish a current unexpired product-specific exclusivity period that would block all competing biologic entry.
What patents protect ARALAST NP?
ARALAST NP does not have the typical Orange Book patent profile associated with branded tablets, capsules, or injectable small molecules. Biologic patent information is handled through the Purple Book and the BPCIA patent-exchange process rather than routine Orange Book listing.
Publicly available sources do not establish a current, product-specific ARALAST NP patent estate with broad blocking claims covering the active protein itself. The protein is a naturally occurring human plasma protein, and the commercial product has been marketed for many years.
Potentially relevant patent categories include:
- Formulation patents covering stabilizers, drying conditions, reconstitution, or storage.
- Manufacturing patents covering purification, viral inactivation, filtration, and fractionation.
- Plasma-pooling and pathogen-reduction processes.
- Container, administration, or delivery configurations.
- Method-of-use claims directed to augmentation therapy or treatment of deficiency-associated emphysema.
These categories may create development costs for a competitor, but they do not necessarily prevent biosimilar approval. A biosimilar applicant can challenge patents, design around process claims, or enter after patent expiry.
What is the Orange Book status of ARALAST NP?
ARALAST NP is not expected to have a conventional Orange Book listing because it is a biologic rather than an NDA-approved small-molecule drug. The relevant FDA reference is the Purple Book, which identifies licensed biological products and biosimilar relationships.[4]
A Paragraph IV certification is therefore not the normal challenge mechanism. A biosimilar applicant would use the BPCIA patent-dispute process, including patent information exchange and potential declaratory or infringement litigation.
Which companies compete with ARALAST NP?
ARALAST NP competes in a concentrated U.S. market for intravenous A1PI augmentation therapy.
| Product |
Company |
Product type |
Commercial relevance |
| ARALAST NP |
Takeda |
Plasma-derived A1PI |
Established incumbent with long market history |
| Prolastin-C |
Grifols |
Plasma-derived A1PI |
Major competitor with broad physician and infusion-center presence |
| Zemaira |
CSL Behring |
Plasma-derived A1PI |
Established competing product |
| Glassia |
Kamada |
Plasma-derived A1PI |
Competes through product availability and provider relationships |
Competition is based less on molecular differentiation than on supply continuity, distribution, infusion logistics, payer contracts, patient-support services, and physician confidence.
No approved interchangeable biosimilar or follow-on A1PI product has materially reshaped the U.S. market in the public regulatory record through the latest cited FDA materials. The absence of biosimilar competition supports pricing stability but also reflects the complexity of plasma collection, fractionation, viral safety validation, and clinical development.
What drives ARALAST NP market demand?
Demand is determined by the number of diagnosed patients with severe A1PI deficiency, treatment eligibility, payer coverage, and willingness to maintain weekly infusions.
Diagnosed patient pool
Alpha1-antitrypsin deficiency is underdiagnosed. Estimates of disease prevalence vary by genotype, geography, and diagnostic method. Severe deficiency is far less common than mild or heterozygous deficiency, while only a subset develop clinically significant emphysema or liver disease.
The addressable treatment population is therefore much smaller than the total number of people carrying an SERPINA1 mutation.
Chronic treatment model
ARALAST NP is generally administered weekly. This creates recurring revenue per treated patient and reduces dependence on new-patient starts. It also increases exposure to:
- Home-infusion capacity.
- Nurse and pharmacy coordination.
- Patient adherence.
- Payer authorization and reauthorization.
- Intravenous access requirements.
- Product shortages or plasma constraints.
Plasma supply
Plasma is the central manufacturing constraint. Production depends on donor recruitment, collection-center capacity, fractionation infrastructure, pathogen-control processes, and release testing. A shortage can affect all major A1PI suppliers and can shift demand between products.
Reimbursement
Treatment is expensive because it is a lifelong biologic replacement therapy with weekly administration. Payers evaluate diagnosis, genotype, serum A1PI concentration, pulmonary function, emphysema documentation, and evidence supporting augmentation therapy. Coverage policies can vary by commercial insurer, Medicare contractor, and state.
What is the financial trajectory of ARALAST NP?
Takeda does not disclose ARALAST NP revenue as a standalone line item in its public annual reports. The product is included within broader business segments and product categories, preventing a reliable public calculation of sales, gross margin, or contribution profit.[5]
The likely financial trajectory has four phases:
| Phase |
Financial characteristics |
| Initial launch and adoption |
Growth driven by diagnosis expansion, physician education, and conversion from earlier ARALAST supply |
| Mature specialty product |
Recurring weekly utilization and relatively stable treated-patient base |
| Portfolio transition |
Ownership changes from Baxter to Baxalta, then Shire and Takeda |
| Mature biologic competition |
Revenue influenced by plasma availability, payer pressure, competitor supply, and potential biosimilar activity |
ARALAST NP is more likely to be a stable specialty-revenue product than a high-growth asset. Its revenue base benefits from chronic therapy and low patient turnover. Growth is constrained by the small diagnosed population and the absence of a broad new indication.
Public disclosures do not support an exact estimate of:
- Annual ARALAST NP sales.
- Takeda’s product-level operating margin.
- U.S. versus international revenue.
- Patient count.
- Net price after rebates.
- Revenue loss from competitor switching.
- Product-specific cash flow.
Any precise revenue figure presented without a company disclosure or audited market dataset would be speculative.
How strong is the ARALAST NP patent estate?
The patent estate appears weaker as a direct blocking tool than the manufacturing and supply-chain barriers.
| Protection category |
Commercial strength |
| Active protein composition |
Limited, because A1PI is a naturally occurring human protein |
| Core indication |
Moderate if supported by valid method claims, but clinical-use claims may be designed around |
| Formulation |
Potentially meaningful if specific excipients or stability parameters are protected |
| Manufacturing process |
Stronger practical barrier because plasma fractionation and viral-safety processes are difficult to replicate |
| Plasma supply |
High commercial barrier, although not a patent right |
| Regulatory history |
Important for market credibility and physician adoption |
| Distribution and reimbursement |
Material commercial barrier but not intellectual property |
For a challenger, process replication and reliable plasma procurement may be more difficult than overcoming an expired or narrow formulation patent. For Takeda, the most durable defenses are likely manufacturing expertise, supply contracts, quality systems, and market access.
What generic or biosimilar entry risks exist?
Conventional generic entry is not the relevant risk. A competing company would need to pursue a biosimilar or a separate biologics license supported by analytical, manufacturing, and clinical evidence.
The main entry scenarios are:
Biosimilar entry
A biosimilar applicant could seek approval by demonstrating high similarity to the reference product and addressing residual uncertainty through targeted clinical or pharmacokinetic studies. Patent litigation could occur under the BPCIA, but no current approved biosimilar has displaced ARALAST NP.
Competing plasma-derived product
A company could develop another A1PI product without seeking biosimilar status. This route would require plasma supply, manufacturing infrastructure, clinical evidence, and FDA review. It could produce a product that competes commercially without being interchangeable.
Supply-driven switching
A shortage at one manufacturer can cause temporary switching to competitors. These switches may persist if physicians and payers accept the substitute product.
Price-driven erosion
Because the patient population is concentrated and treatment is recurring, a competitor with lower net pricing could win contracts from infusion providers and payers even without interchangeability.
What patent litigation or settlement agreements affect ARALAST NP?
No major, publicly documented Paragraph IV litigation or generic settlement agreement is associated with ARALAST NP in the manner seen with branded small-molecule drugs. The absence of a conventional Orange Book listing makes Paragraph IV litigation unlikely.
Publicly available information also does not establish a major BPCIA biosimilar settlement involving ARALAST NP. Product-specific litigation risk is more likely to arise from manufacturing patents, trade secrets, regulatory exclusivity disputes, supply agreements, or commercial-contract claims than from classic Hatch-Waxman litigation.
How does ARALAST NP compare with Prolastin-C, Zemaira, and Glassia?
| Factor |
ARALAST NP |
Prolastin-C |
Zemaira |
Glassia |
| Molecule class |
Plasma-derived A1PI |
Plasma-derived A1PI |
Plasma-derived A1PI |
Plasma-derived A1PI |
| Administration |
IV |
IV |
IV |
IV |
| Core market |
Severe hereditary A1PI deficiency |
Same |
Same |
Same |
| Differentiation |
Formulation, supply, support, contracting |
Brand scale and market presence |
CSL plasma and specialty distribution |
Supplier strategy and availability |
| Main risk |
Mature-market erosion and supply competition |
Same |
Same |
Same |
| Generic substitution |
No conventional generic |
No conventional generic |
No conventional generic |
No conventional generic |
| Biosimilar risk |
Possible but limited to date |
Possible |
Possible |
Possible |
The products are clinically similar at the treatment-category level, so commercial differentiation depends heavily on supply reliability, infusion services, payer positioning, and patient support.
What geographic markets matter for ARALAST NP?
The United States is likely the most important market because of its established augmentation-therapy infrastructure and high specialty-drug spending. European and other international markets are governed by country-specific reimbursement rules, plasma regulation, and national treatment guidelines.
Geographic barriers include:
- Different diagnostic rates.
- National reimbursement restrictions.
- Local plasma-supply rules.
- Country-specific biologic approvals.
- Varying acceptance of augmentation therapy.
- Distribution and cold-chain requirements.
A product can maintain U.S. demand while facing slower international growth if reimbursement authorities restrict treatment to specific genotypes or pulmonary-function thresholds.
Key Takeaways
- ARALAST NP is a mature plasma-derived biologic for weekly augmentation therapy in severe hereditary alpha1-antitrypsin deficiency.
- Takeda does not separately report ARALAST NP revenue, so product-level financial performance cannot be independently quantified from public filings.
- Conventional generic entry and Paragraph IV challenges are not the primary risks because ARALAST NP is a biologic.
- No current product-specific statutory exclusivity period appears to block competition.
- The strongest barriers are plasma supply, manufacturing quality, viral-safety controls, regulatory experience, payer access, and infusion infrastructure.
- Prolastin-C, Zemaira, and Glassia are the principal U.S. commercial comparators.
- Biosimilar entry is legally possible but operationally difficult, and no approved biosimilar has materially altered the market in the cited FDA record.
- ARALAST NP is best characterized as a mature, recurring-revenue specialty biologic with limited diagnosed-population growth and meaningful supply-chain protection.
FAQs
Is ARALAST NP still FDA approved?
ARALAST NP is identified in FDA prescribing information as an approved alpha1-proteinase inhibitor product for augmentation therapy in adults with severe hereditary deficiency and emphysema.[1]
Is ARALAST NP interchangeable with Prolastin-C?
No automatic interchangeability should be assumed. Products in the same therapeutic class are not interchangeable unless FDA grants the relevant designation or the applicable substitution rules permit it.
Does ARALAST NP have an Orange Book patent?
ARALAST NP is a biologic and is not expected to have the conventional Orange Book patent profile of an NDA-approved small-molecule drug. Biologic reference-product and patent information is evaluated through the Purple Book and BPCIA framework.
What is the main commercial risk to ARALAST NP?
The main risks are competitor supply reliability, payer pressure, plasma availability, diagnosis and treatment limits, and potential development of a biosimilar or competing A1PI product.
Can ARALAST NP revenue be estimated from Takeda’s annual report?
Not with product-level precision. Takeda reports at business-segment and broader product-group levels rather than disclosing a standalone ARALAST NP revenue line.[5]
References
- U.S. Food and Drug Administration. (n.d.). ARALAST NP: Alpha1-proteinase inhibitor (human) prescribing information.
- U.S. Food and Drug Administration. (2003). ARALAST approval and biologics regulatory materials.
- U.S. Food and Drug Administration. (2024). Reference product exclusivity for biological products.
- U.S. Food and Drug Administration. (n.d.). Purple Book: Database of licensed biological products.
- Takeda Pharmaceutical Company Limited. (2024). Annual report and consolidated financial results.
